TxCell SA has announced that the Japan Patent Office has indicated that it intends to grant to TxCell a key patent in Japan to cover its lead product Ovasave® and its application to inflammatory bowel disease (IBD). Specifically, the patent covers the administration of a composition that consists of at least one human Type-1 Treg cell population directed against a food antigen from the common human diet.
The equivalent patent has already been granted in the USA (2015), Australia (2015) and Russia (2013). Other corresponding patent applications for Ovasave in IBD are pending in major markets globally. TxCell now owns or controls more than 126 patents that provide coverage for its first platform ASTrIA. These patents are related to the characterisation, production and use of Ag-Tregs for the treatment of chronic autoimmune inflammatory diseases.
"Recent positive developments in both the regulatory field and product approvals means that
Japan has become a key market for cellular immunotherapy,” said Stéphane Boissel, Chief
Executive Officer of TxCell. “The grant of this latest key patent in Japan will help to achieve
TxCell’s ambitious objectives in expanding our global reach.
In addition, TxCell has dedicated years of effort in research and development to establish a robust international intellectual property portfolio. This patent coverage will be critical for our ongoing efforts to make cellular immunotherapies available to the large number of patients with a variety of conditions with unmet medical need.”